Journal of the Egyptian National Cancer Institute 2021

1 papers

Top Research Directions

The 5 research directions with Journal of the Egyptian National Cancer Institute 2021 papers, ranked by paper count. Share is the fraction of the edition’s papers in the direction.

#DirectionPapersShare
1Histopathological Ground Truth for Non-Invasive Diagnostics1100.0%
2Minimally Invasive Alternatives to Radical Open Surgery1100.0%
3Predicting Occult Metastasis with Radiomics and Machine Learning1100.0%
4Selection Bias in Historical Clinical Datasets1100.0%
5Weighted Linear Models for Molecular Risk Stratification1100.0%

Download all directions as CSV

Institutions

Institutions credited by Journal of the Egyptian National Cancer Institute 2021 papers: a paper credits every institution named in its affiliations, once. 2 institutions share 1 credited papers.

#InstitutionPapersShare
1021zm6p18 1100.0%
2Cairo University 1100.0%

Download all institutions as CSV

About this data

Papers. Journal of the Egyptian National Cancer Institute 2021 lists 1 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 1 of 1 papers (100.0%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-17 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Journal of the Egyptian National Cancer Institute 2021”, https://lacuna.tiptreesystems.com/venue/journal-of-the-egyptian-national-cancer-institute/2021.

Papers

Title
The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery